“Real-World Effectiveness and Safety of Nemolizumab in Moderate-to-Severe Atopic Dermatitis: A Phase IV, Prospective, Non-Interventional Study Design From RE-UNITE-AD (NCT06988605)” (2026) SKIN The Journal of Cutaneous Medicine, 10(2), p. s746. doi:10.25251/nq0ynj58.